EZH2

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, April 10, 2024
Novartis, ASH, Tafasitamab, Webcast, Purchasing, EZH1, EDT, Acquisition, Standard of care, BET, Business analyst, EZH2, Ruxolitinib, Exposition, Society, Safety, Anemia, GMT, MorphoSys, JAK, Annual general meeting, Pharmaceutical industry

“Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.

Key Points: 
  • “Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.
  • With its ample resources, additional scientific expertise and global footprint, Novartis can help accelerate pelabresib's potential worldwide.
  • Total revenues for the fourth quarter 2023 were € 59.0 million compared to € 81.6 million for the same period in 2022.
  • The decrease resulted first and foremost from prior year revenues stemming from the execution of an out-licensing agreement with Novartis.

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
PRC2, Prostate cancer, Regulation, EED, Cell, Patient, CYP, SAN, Doctor of Philosophy, EZH2, AACR, TRIM37, PLK4, Optimism, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, and presentation of a new discovery candidate, ORIC-613, an orally bioavailable, potent and selective PLK4 inhibitor, at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors
    First data presentation on ORIC-613, a potential first- and best-in-class development candidate selectively inhibiting PLK4
    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, and presentation of a new discovery candidate, ORIC-613, an orally bioavailable, potent and selective PLK4 inhibitor, at the 2024 American Association for Cancer Research (AACR) Annual Meeting.
  • “ORIC-944 in combination with AR inhibitors demonstrates anti-tumor activity in multiple AR-positive prostate cancer models, supporting the planned expansion of our ORIC-944 clinical program in combination with AR inhibitors in metastatic prostate cancer,” said Lori Friedman, PhD, chief scientific officer.
  • “These encouraging preclinical findings, coupled with potential best-in-class drug properties and deepened understanding of the mechanism driving synergy, fuel our optimism for advancing this program.
  • Additionally, the unveiling of preclinical characterization of ORIC-613, a potential first- and best-in-class selective PLK4 inhibitor, marks a significant milestone in our discovery program, with preclinical data demonstrating synthetic lethality in TRIM37-high tumors.”
    ORIC-944, a potent and selective allosteric PRC2 inhibitor with potential best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models (Presentation will be available on ORIC website on Tuesday, April 9, 2024 at 2:30 p.m. PT)
    Key findings of the presentations:
    Discovery of ORIC-944 was enabled through structure-based drug design and leveraged a cryptic pocket in an allosteric site in EED, a subunit of PRC2
    Comprehensive profiling supports ORIC-944's best-in-class properties versus competitor PRC2 inhibitors, including PF-06821497, tazemetostat, and CPI-0209:
    Clinical half-life estimated at approximately 20 hours, with no sign of CYP autoinduction that is observed with first-generation PRC2 inhibitors
    Demonstrated that EED and EZH2 inhibitors act through the same mechanism of action, making prostate cancer cells more susceptible to AR inhibition:
    Transcriptional changes induced by ORIC-944 were comparable to those of EZH2 inhibitors in prostate cancer models, indicating no mechanistic distinction between molecules targeting different core subunits of PRC2
    RNA sequencing of prostate cancer models revealed that ORIC-944 increases AR signaling and luminal cell fate, thereby rendering these cells more susceptible to AR inhibition
    ORIC-613, a potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models
    Key findings of the presentation:
    ORIC-613 is an orally bioavailable, potent and exquisitely selective small molecule inhibitor of PLK4, which is synthetic lethal in tumor cells with high levels of TRIM37
    Preclinical assessment in cancer cell lines revealed synthetic lethality, with ORIC-613 inducing apoptotic tumor cell death specifically in TRIM37-high breast cancer and neuroblastoma cells versus TRIM37-wildtype cells
    These results position ORIC-613 as a potential first- and best-in-class development candidate, which has the potential to benefit patients with TRIM37-high tumors

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

Retrieved on: 
Wednesday, February 28, 2024
Neoplasm, RMB, SHPL, Net, EZH2, Growth, FC, Tax, Follicular lymphoma, FX, Fast Track, TCFD, Ethics, Marketing, RCC, Health, CER, Sintilimab, ITP, Disclosure, Plasma protein binding, Lancet, MET, Completeness, D-19, Paclitaxel, Met, NDA, NSCLC, EGFR, NRDL, Atopic dermatitis, ESG, CRC, PD-1, Completion, Phases of clinical research, Task force, Half-life, Chills, Potential, Breakthrough therapy, NMPA, Investment, FGFR, Research, PFS, AstraZeneca, EMA, ADS, Annual report, ASCO, FDA, Carbon accounting, VEGFR, Lung, COVID-19, Alopecia areata, PMDA, Lilly, Patient, Cancer, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:​HCM; HKEX:​13), the innovative, commercial-stage biopharmaceutical company, today reports its financial results for the year ended December 31, 2023 and provides updates on key clinical and commercial developments. HUTCHMED to host results call and webcasts today at 7:30 a.m. EST / 12:30 p.m. GMT / 8:30 p.m. HKT in English, and at 8:30 a.m. HKT in Chinese (Putonghua) on Thursday, February 29, 2024.

Key Points: 
  • HUTCHMED is committed to progressively embedding sustainability into all aspects of our operations and creating long-term value for our stakeholders.
  • The 2023 Sustainability Report will be published alongside our 2023 Annual Report in April 2024 and will include further information on HUTCHMED sustainability initiatives and their performance.
  • Net Income attributable to HUTCHMED for 2023 was $100.8 million compared to Net Loss attributable to HUTCHMED of $360.8 million in 2022.
  • The net income attributable to HUTCHMED in 2023 was $0.12 per ordinary share / $0.59 per ADS49, compared to net loss attributable to HUTCHMED of $0.43 per ordinary share / $2.13 per ADS in 2022.

EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Retrieved on: 
Tuesday, February 6, 2024
Slate, Partnership, Supervisory board, Centerview Partners, Immediate, Novartis, Tender offer, Tafasitamab, Purchasing, EZH2, Ruxolitinib, Patient, BET, Workforce, GMT, EZH1, Federal Financial Supervisory Authority, Disease, Acquisition, AG, EST, Business analyst, Webcast, Cancer, Schedule, Pharmaceutical industry

Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to Incyte Corporation (“Incyte”).

Key Points: 
  • Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to Incyte Corporation (“Incyte”).
  • “Novartis shares our steadfast commitment to develop and deliver transformative medicines that address the dire needs of cancer patients.
  • Novartis intends to offer MorphoSys’ shareholders € 68.00 per share in cash, for a total equity value of € 2.7 billion.
  • Creates New Opportunities for MorphoSys’ Colleagues: The agreement between Novartis and MorphoSys includes employee commitments.

Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board

Retrieved on: 
Wednesday, January 10, 2024
Stanford University, Leukemia, Monroe Dunaway Anderson, Research, Metastasis, Ipilimumab, Cancer, Autoimmune disease, CODEX, GBM, University, National academy, Bladder cancer, MD Anderson Cancer Center, RNA, Teal, CD28, Defense, EZH2, Nobel Prize, Invention, Translational research, Health, Cell biology, Pathology, Woman, Immunotherapy, SAB, Emil Frei, Patient, Associate, MD, Roche, Burroughs Wellcome Fund, Society, FDA, ATAC, ASCI, Doctor of Philosophy, Clinical trial, Immune system, Pharmaceutical industry

Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB.

Key Points: 
  • Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB.
  • He co-founded Akoya Biosciences in 2015 and is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine.
  • Dr. Allison has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy.
  • This finding and a great deal of persistence paved the way for the field of immune checkpoint blockade therapy for cancer.

ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Oncology, Biology, Ipsen, University of Jena, Science, Drug discovery, Autoimmune disease, Autoimmunity, Research, FDA, Disease, Therapy, EZH2, Inflammation, AKT, Biochemistry, PARP, Merck, Patient, Harvard Medical School, History, Pharmaceutical industry

ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced the appointment of cancer biology and immunology expert Heike Keilhack, Ph.D., as Chief Scientific Officer.

Key Points: 
  • ROME Therapeutics , a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced the appointment of cancer biology and immunology expert Heike Keilhack, Ph.D., as Chief Scientific Officer.
  • Dr. Keilhack brings to ROME more than 20 years of experience leading target validation and preclinical and translational efforts for multiple first-in-class therapeutics at both small biotechnology companies and large pharmaceutical companies.
  • “I was drawn to ROME because of its compelling scientific approach to drug discovery and development, as well as its highly talented team of business and scientific leaders,” said Dr. Keilhack.
  • I am excited to work as part of the ROME team as we uncover and advance this science toward helping patients who need new options.”

ENSEM Expands its Leadership Team with the Appointment of Jeff Kutok, M.D., Ph.D. as Chief Scientific Officer

Retrieved on: 
Wednesday, January 3, 2024
Associate, Ipsen, Hospital, Science, Partnership, Duvelisib, Biotechnology, Drug development, Research, Pathology, Acquisition, BWH, Brigham and Women's Hospital, Therapy, EZH2, Verastem Oncology, Hematology, Stony Brook University, PI3K, Kinetic, Patient, Harvard Medical School, AbbVie, Management

WALTHAM, Mass., Jan. 3, 2024 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the appointment of Dr. Jeff Kutok as Chief Scientific Officer, effectively immediately.

Key Points: 
  • WALTHAM, Mass., Jan. 3, 2024 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the appointment of Dr. Jeff Kutok as Chief Scientific Officer, effectively immediately.
  • "Dr. Kutok is a seasoned executive with the right credentials to guide ENSEM's science into the future," stated Shengfang Jin, Ph.D., President & Chief Executive Officer of ENSEM.
  • Dr. Kutok previously served as Executive Vice President and Chief Scientific Officer at Infinity Pharmaceuticals, Inc. where he was responsible for the company's scientific strategy, preclinical development, and translational science.
  • "I am thrilled to join the ENSEM team at this exciting time," stated Dr. Jeff Kutok, Chief Scientific Officer at ENSEM.

2023 Urology Care Foundation Research Scholar Awardees Announced

Retrieved on: 
Tuesday, December 19, 2023
University, Vanderbilt University Medical Center, Cancer, Ageing, Urology, Pelvic pain, Houston Methodist Hospital, Spinal cord, The, EZH2, Randomized controlled trial, System, DNMT, Memorial, Weill Cornell Medicine, Children, Patient, American Urological Association, Hospital, FACS, Ureteroscopy, Research, Cornell University, AUA, Prostate cancer, Doctor of Philosophy, Macrophage, Funding of science, Children's Hospital of Philadelphia, Nursing

BALTIMORE, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 13 researchers as recipients of the 2023 Urology Care Foundation Research Scholar Awards.

Key Points: 
  • BALTIMORE, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 13 researchers as recipients of the 2023 Urology Care Foundation Research Scholar Awards.
  • Research Scholar Awards support future research leaders and ensure they receive the necessary training and guidance for a successful research career.
  • "The Urology Care Foundation is dedicated to improving urologic health worldwide by supporting research, providing patient education materials, and promoting humanitarian initiatives,” said Harris M Nagler, MD, FACS, Urology Care Foundation President.
  • “We are proud of our 2023 awardees and recognize the substantial impact their work will have on advancing the field of urology.”
    To learn more about the Urology Care Foundation Research Scholar Awards visit: https://www.auanet.org/research-and-data/research-awards/aua-funding/res...

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Pharmaceutical, Health, Oncology, FSE, EZH1, Annual general meeting, PST, Food, JAK, ASH, Patient, ARID1A, FDA, Abstract, EST, Society, Ruxolitinib, EZH2, Fast Track, BET, Pharmaceutical industry, Video game, Tafasitamab, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.
  • “Sales of Monjuvi remain on track for its approved indication, allowing us to narrow our full-year 2023 guidance target.
  • Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
  • Events After the End of the Third Quarter of 2023:
    MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.

EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, December 14, 2023
Annual general meeting, Food, Fast Track, Ruxolitinib, Conference call, BET, FSE, EZH2, CET, EZH1, JAK, Society, FDA, ASH, Abstract, PST, Patient, Conference, Webcast, ARID1A, Pharmaceutical industry, Cryptocurrency, Video game, Tafasitamab, MorphoSys

“With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.

Key Points: 
  • “With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.
  • Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
  • Events After the End of the Third Quarter of 2023:
    MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.
  • Total revenues for the third quarter 2023 were € 63.8 million compared to € 95.8 million for the same period in 2022.